NASDAQ · TWST
Healthcare · Medical - Diagnostics & Research
$153.10
Up+$3.04 (+2.03%)
Updated Aug 28, 2026, 9:07 AM
SID Score
5.6/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
TWST closed at $153.10 after 21 trading sessions, up 67.63% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 27, 2026 | $149.23 | $155.44 | $148.4357 | $153.10 | 1.25M |
| Aug 26, 2026 | $148.00 | $153.9999 | $147.00 | $150.06 | 1.21M |
| Aug 25, 2026 | $145.73 | $154.96 | $141.41 | $151.42 | 2.08M |
| Aug 24, 2026 | $145.37 | $145.41 | $137.37 | $140.80 | 1.81M |
| Aug 21, 2026 | $138.43 | $145.93 | $135.05 | $145.59 | 1.8M |
| Aug 20, 2026 | $136.84 | $145.51 | $135.17 | $136.33 | 2.4M |
| Aug 19, 2026 | $128.00 | $142.84 | $127.75 | $142.39 | 3.55M |
| Aug 18, 2026 | $121.61 | $123.295 | $115.28 | $116.10 | 1.3M |
| Aug 17, 2026 | $116.91 | $124.98 | $116.91 | $124.41 | 977.39K |
| Aug 14, 2026 | $124.09 | $124.7052 | $118.44 | $118.57 | 1.14M |
| Aug 13, 2026 | $126.22 | $126.40 | $122.14 | $125.29 | 912.21K |
| Aug 12, 2026 | $123.96 | $125.38 | $120.50 | $125.21 | 1.61M |
| Aug 11, 2026 | $125.625 | $125.625 | $120.65 | $123.12 | 1.06M |
| Aug 10, 2026 | $113.56 | $125.66 | $113.18 | $124.88 | 2.64M |
| Aug 7, 2026 | $110.89 | $118.32 | $109.2601 | $115.67 | 1.56M |
| Aug 6, 2026 | $113.76 | $113.76 | $108.62 | $109.08 | 1.83M |
| Aug 5, 2026 | $104.50 | $115.56 | $104.49 | $115.01 | 3.3M |
| Aug 4, 2026 | $106.58 | $106.58 | $98.89 | $99.445 | 1.25M |
| Aug 3, 2026 | $81.595 | $102.34 | $80.59 | $101.06 | 2.94M |
| Jul 31, 2026 | $93.068 | $93.57 | $88.3001 | $91.55 | 1.49M |
| Jul 30, 2026 | $87.75 | $91.915 | $86.495 | $91.33 | 1.66M |
The latest Smart Investors Daily articles mentioning TWST.
TWST research
Company profile and research snapshot.
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 5, 2026 | Piper Sandler | Overweight | — |
| Aug 4, 2026 | Baird | Outperform | — |
| Jul 14, 2026 | Canaccord Genuity | Buy | — |
| Jul 6, 2026 | Evercore ISI Group | In-Line | — |
| Jun 29, 2026 | Guggenheim | Buy | — |
No generated briefing is available yet.
SeekingAlpha · Aug 20, 2026
Twist Bioscience Corporation a Hold: $9.5B valuation vs. fundamentals, big surge on AI/short squeeze, guidance raised but losses persist. Click for this TWST update.
Benzinga · Aug 19, 2026
TWST shares surge after Anthropic names the company an independent evaluator in a new AI-driven protein design campaign. The bullish momentum overshadows a critical short report published on X by activist short-seller Scorpion Capital.
Benzinga · Aug 19, 2026
https://x.com/ScorpionFund/status/2090160099520348644?s=20
Benzinga · Aug 19, 2026
Twist Bioscience (TWST) stock jumped 17% after Anthropic chose the firm to test AI-designed proteins. Get the full market update.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning TWST.
